CIP2A is known to be overexpressed in several cancer types, and its overexpression has been demonstrated to associate with reduced survival for example in gastric cancer 20, serous ovarian carcinoma 21, nonsmall‐cell lung carcinoma 22, chronic myeloid leukemia 23, CRC 24, and head and neck squamous cell carcinoma (HNSCC) 25. This evidence concerns the gene CIP2A and head and neck squamous cell carcinoma.